| 001 | 147215 | ||
| 005 | 20240229112643.0 | ||
| 024 | 7 | _ | |a 10.1016/S1470-2045(19)30503-0 |2 doi |
| 024 | 7 | _ | |a pmid:31582354 |2 pmid |
| 024 | 7 | _ | |a 1470-2045 |2 ISSN |
| 024 | 7 | _ | |a 1474-5488 |2 ISSN |
| 024 | 7 | _ | |a altmetric:67500436 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-02341 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Herling, Carmen D |b 0 |
| 245 | _ | _ | |a Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. |
| 260 | _ | _ | |a London |c 2019 |b The Lancet Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1573819976_28760 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 20(11):1576-1586 |
| 520 | _ | _ | |a Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Coombes, Kevin R |b 1 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 2 |u dkfz |
| 700 | 1 | _ | |a Bloehdorn, Johannes |b 3 |
| 700 | 1 | _ | |a Barron, Lynn L |b 4 |
| 700 | 1 | _ | |a Abrams, Zachary B |b 5 |
| 700 | 1 | _ | |a Majewski, Tadeusz |b 6 |
| 700 | 1 | _ | |a Bondaruk, Jolanta E |b 7 |
| 700 | 1 | _ | |a Bahlo, Jasmin |b 8 |
| 700 | 1 | _ | |a Fischer, Kirsten |b 9 |
| 700 | 1 | _ | |a Hallek, Michael |b 10 |
| 700 | 1 | _ | |a Stilgenbauer, Stephan |b 11 |
| 700 | 1 | _ | |a Czerniak, Bogdan A |b 12 |
| 700 | 1 | _ | |a Oakes, Christopher C |b 13 |
| 700 | 1 | _ | |a Ferrajoli, Alessandra |b 14 |
| 700 | 1 | _ | |a Keating, Michael J |b 15 |
| 700 | 1 | _ | |a Abruzzo, Lynne V |b 16 |
| 773 | _ | _ | |a 10.1016/S1470-2045(19)30503-0 |g p. S1470204519305030 |0 PERI:(DE-600)2035574-9 |n 11 |p 1576-1586 |t The lancet |v 20 |y 2019 |x 1470-2045 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:147215 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LANCET ONCOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF >= 30 |0 StatID:(DE-HGF)9930 |2 StatID |b LANCET ONCOL : 2017 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::